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Colocalization of human Rad17 and PCNA in late S phase of the
cell cycle upon replication block
Abstract
In response to replication block or DNA damage in S phase the DNA replication and DNA damage
checkpoints are activated. The current model in human predicts, that a Rad17/Replication factor C
(RF-C) complex might serve as a recruitment complex for the Rad9/Hus1/Rad1 complex to sites of
replication block or DNA damage. In this study we have investigated the fate of the Rad17/RF-C
complex after treatment of synchronized Hela cells with the replication inhibitor hydroxyurea. In
hydroxyurea treated cells the RF-C p37 subunit became more resistant to extraction. Moreover,
co-immunoprecipitation studies with extracts of hydroxyurea treated cells showed an interaction of
RF-C p37 with Rad17 and of PCNA with Rad9 and RF-C p37. An enhanced colocalization of Rad17
and PCNA in late S phase after hydroxyurea treatment was observed. Our data suggested, that upon
replication block a Rad17/RF-C complex is recruited to sites of DNA lesions in late S phase, binds the
Rad9/Hus1/Rad1 complex and enables it to interact with PCNA. An interaction of Rad17/RF-C with
PCNA appears to be mediated by the small RF-C p37 subunit, suggesting that PCNA might provide
communication between replication checkpoint control and DNA replication and repair.
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In response to replication block or DNA damage in S
phase the DNA replication and DNA damage check-
points are activated. The current model in human
predicts, that a Rad17/Replication factor C (RF-C)
complex might serve as a recruitment complex for the
Rad9/Hus1/Rad1 complex to sites of replication block
or DNA damage. In this study we have investigated the
fate of the Rad17/RF-C complex after treatment of
synchronized Hela cells with the replication inhibitor
hydroxyurea. In hydroxyurea treated cells the RF-C p37
subunit became more resistant to extraction. Moreover,
co-immunoprecipitation studies with extracts of hydro-
xyurea treated cells showed an interaction of RF-C p37
with Rad17 and of PCNA with Rad9 and RF-C p37. An
enhanced colocalization of Rad17 and PCNA in late S
phase after hydroxyurea treatment was observed. Our
data suggested, that upon replication block a Rad17/RF-
C complex is recruited to sites of DNA lesions in late S
phase, binds the Rad9/Hus1/Rad1 complex and enables
it to interact with PCNA. An interaction of Rad17/RF-C
with PCNA appears to be mediated by the small RF-C
p37 subunit, suggesting that PCNA might provide
communication between replication checkpoint control
and DNA replication and repair.
Oncogene (2002) 21, 7710 – 7719. doi:10.1038/sj.onc.
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Introduction
In response to replication block or DNA damage in the
DNA synthesis phase (S phase) of the cell cycle
eukaryotic cells slow down progression through S
phase and delay the onset of mitosis (M). These
responses are summarized as intra S and S/M
replication checkpoint and DNA damage checkpoint.
Studies in budding yeast showed, that the slowing
down of S phase progression is due to suppression of
replication from late origins (Santocanale and Diey,
1998, Shirahige et al., 1998) and allows the stabiliza-
tion of existing replication forks (Tercero and Diey,
2001, Lopes et al., 2001). The replication checkpoint
also directly targets components of the replication
machinery. It is assumed, that the DNA replication
checkpoint serves to maintain the replisome and fork
in an open and competent structure (Donaldson and
Blow, 2001). Studies in fission yeast have shown a role
for members of the so-called Rad protein family,
including Rad17, Rad1, Rad9 and Hus1, in the
activation of DNA replication and DNA damage
checkpoints (Mitchell, 2001). Replication factor C
(RF-C), a pentameric protein complex, serves as a
clamp loader for proliferating cell nuclear antigen
(PCNA) in DNA replication and repair (Mossi and
Hu¨bscher, 1998). In yeast, RF-C subunits also function
in the DNA replication and DNA damage checkpoint
control pathways. Fission and budding yeast cells
carrying a deletion or mutation in genes encoding small
RF-C subunits are defective in the DNA replication
and DNA damage checkpoint functions (Reynolds et
al., 1999; Shimada et al., 1999; Noskov et al., 1998;
Gary Schmidt et al., 2001; Sugimoto et al., 1996, 1997).
An alternative RF-C complex consisting of the four
small RF-C subunits and cell cycle checkpoint protein
Rad24/Rad17 was isolated from uncompromised
budding yeast (Green et al., 2000) and human cells
(Lindsey-Boltz et al., 2001). Using in vitro transcribed/
translated human (h) RF-C subunits and hRad17 it
was shown, that complex formation is dependent on
interaction of hRad17 with the p38 subunit of hRF-C.
Purified hRad17/hRF-C complex has similar properties
like replicative hRF-C: it exhibits ATPase activity,
which can be strongly stimulated by ssDNA and binds
preferentially to primed DNA. In contrast to replica-
tive hRF-C, however, the ATPase activity of hRad17/
hRF-C complex is not stimulated by PCNA (Lindsey-
Boltz et al., 2001).
By yeast two hybrid analysis it was shown that
hRad17 interacts with hRad1 (Parker et al., 1998). The
checkpoint proteins hRad9, hHus1, and hRad1 can be
co-immunoprecipitated with hRad17 from human cell
extracts (Rauen et al., 2000). Structure and sequence
based alignments predict that hRad9, hHus1, and
hRad1 form a PCNA like clamp (Venclovas and
Thelen, 2000). hRad9, hHus1, and hRad1 expressed in
baculovirus infected insect cells indeed form a trimeric
complex like PCNA (Burtelow et al., 2001). Electron
microscopical analyses showed that Rad17/RF-C
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complexes form U-shaped particles resembling replica-
tive RF-C and that hRad9/hHus1/hRad1 (9-1-1)
complexes form flat rings with a distinct hole very
similar to PCNA (Grith et al., 2002). The hRad17/
hRF-C complex is thought to load the 9-1-1 complex
onto the DNA at the site of a DNA lesion during an
early stage of checkpoint activation (Mitchell, 2001).
Recombinant hRad1 and hRad9 purified from E. coli
exibit 3’-5’exonuclease activity (Parker et al., 1998;
Bessho and Sancar, 2000), suggesting that these proteins
might play a role in the processing of DNA lesions.
Upon treatment with hydroxyurea (HU) or ionizing
radiation the interaction of hHus1 with PCNA is
enhanced, suggesting that PCNA recruits the 9-1-1
complex to sites of replication block or DNA damage
(Komatsu et al., 2000). PCNA is a protein with
multiple interaction partners in DNA metabolism: it
serves as a sliding clamp for polymerase d in DNA
replication and interacts with proteins involved in
Okazaki fragment processing and joining, DNA repair,
DNA methylation, chromatin assembly and cell cycle
checkpoint control (Tsurimoto, 1999). This suggests
that PCNA has a recruiting or coordinating function
for proteins playing a role in the manipulation and the
preservation of the genetic material. PCNA could
provide communication between DNA replication,
DNA repair and cell cycle checkpoint control (Loor
et al., 1997).
In this study we investigated the fate of the hRad17/
hRF-C complex upon treatment of Hela cells with HU
or the DNA damaging agent 4-nitroquinoline (4-NQO)
in S phase. By immunocytochemical analysis we
showed that hRad17 is a constitutively nuclear protein
throughout the cell cycle. hRad17 could be co-
immunoprecipitated with hRF-C p37 from extracts of
HU treated cells, indicating that the hRad17/hRF-C
complex is present in Hela cells under conditions of
replication block. Upon checkpoint activation hRF-C
p37 was recruited to the DNA. Further immunopreci-
pitation experiments revealed that PCNA interacted
with hRad9 and with hRF-C p37 in HU treated cells.
In untreated Hela cells hRad17 colocalized with sites of
BrdU incorporation and PCNA in early S phase, to a
low extent in mid S phase and only marginally in late S
phase. Upon treatment with HU or 4-NQO hRad17
and PCNA showed enhanced colocalization in the late
S phase of the cell cycle. Our data suggest, that a
hRad17/hRF-C complex is recruited to the DNA upon
replication block or DNA damage in late S, binds the
9-1-1 complex and enables it to interact with PCNA.
Our immunocytochemichal data point to a surveyor/
sensor role of hRad17 in early S phase and to a sensor/
signal transmitter role in late S phase.
Results
hRad17 is a constitutively nuclear protein during the cell
cycle
In order to investigate the subcellular localization of
hRad17 during the cell cycle we performed immuno-
cytochemistry with Hela cells synchronized in the G0/
G1, S or G2/M phases of the cell cycle using anti
hRad17 antibody sc-5613. The antibody was mono-
specific in immunoblot analysis with Hela total
extracts for a protein of approximately 76 kD, which
corresponds very well to the theoretical molecular
weight of hRad17 of 75.8 kD. The antibody was also
specific for native GSThRad17 in dot blot analysis
(Figure 1b). In all synchronized cell populations
hRad17 is located in the nucleus showing that it is a
constitutively nuclear protein in Hela cells during the
cell cycle (Figure 1a). We detected a punctuate hRad17
pattern in the nucleoplasm and in some cells a partial
overlap with nucleoli. In contrast to Chang et al.
(1999), however, we did not detect a constitutive and
strong localization of hRad17 in nucleoli in uncom-
promised cells. The same result was obtained,
irrespective whether we used synchronized or unsyn-
chronized cells, paraformaldehyde fixation alone or
paraformaldehyde fixation in combination with a
stepwise dehydration and rehydration with different
methanol dilutions. The differences between our data
and the report by Chang et al. (1999) are likely due to
the usage of different antibodies with different
specificities for immunocytochemical analysis and of
different fixation procedures.
Recruitment of hRF-C p37 to the DNA upon checkpoint
activation
Yeast mutants carrying a deletion of or a mutation in
the gene encoding the hRF-C p37 homologue RF-C2
are deficient in the DNA replication checkpoint
function (Reynolds et al., 1999; Noskov et al., 1998)
or are defective in the S phase DNA damage
checkpoint (Gary Schmidt et al., 2001). By immuno-
blot analysis of total extracts from equivalent Hela cell
numbers we detected increased extraction resistance of
hRF-C p37 at physiological salt conditions in the
presence of ethidiumbromide and 0.1% Triton X-100
after treatment with HU or with the DNA damaging
agent 4-NQO (Figure 2a). Extraction resistant hRF-C
p37 could be released by treatment of cells with S7
nuclease, showing that hRF-C p37 was less extractable
due to recruitment to the DNA (Figure 2b). In these
cells we also detected hyperphosphorylated hRad9
reflecting checkpoint activation (Figure 2a, Chen et
al., 2001b). The increased DNA binding of hRF-C p37
in Hela cells treated with HU or 4-NQO is therefore
caused by the activation of the DNA replication and
DNA damage checkpoint responses. It could reflect
prolonged progression through S phase, in the case of
4-NQO treatment DNA repair or in the case of HU
treatment other checkpoint mediated responses like
stabilization of replication forks. We additionally
observed an increased amount of hRF-C p140 and
hRad9 in S phase cells in comparison to unsynchro-
nized cells, which consist predominantly of cells in G0/
G1. In contrast to hRF-C p140, hRad17 is already
quantitatively extracted at physiological salt conditions
in the presence of ethidiumbromide and 0.1% Triton
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X-100 and showed a similar extraction pattern as the
replication and repair protein PCNA (Figure 2a). The
abundance of hRad17 or hRF-C p37 did not change
following a block to DNA synthesis or DNA damage
(Figure 2c,d).
Interactions of replication proteins and checkpoint Rad
proteins in HU treated cells
In budding yeast the interaction of the hRad17
homologue Rad24 with the small RF-C subunits is
essential for DNA damage checkpoint control through-
out the cell cycle (Naiki et al., 2000). Furthermore,
Rad24 interacts functionally with the small RF-C
subunit RF-C5 in the DNA replication and in the
DNA damage checkpoint pathways. Rad24 can be co-
immunoprecipitated with the small hRF-C subunits
from uncompromised yeast (Shimomura et al., 1998;
Green et al., 2000). We could co-immunoprecipitate
hRad17 with the hRF-C subunit p37 from extracts of
Hela cells treated with HU (Figure 3a), showing that
both proteins interacted under conditions of replication
block in human cells. Additional co-immunoprecipita-
tion experiments revealed, that PCNA interacted with
checkpoint protein hRad9 (Figure 3b), suggesting that
PCNA recruits the 9-1-1 complex to sites of replication
block. The hRad17/hRF-C complex is thought to load
the 9-1-1 complex onto the DNA at the site of a DNA
lesion during an early stage of checkpoint activation
(Mitchell, 2001). After immunoprecipitation of PCNA
from extracts of HU treated cells we could detect co-
immunoprecipitated hRF-C p37 (Figure 3c), but not
hRad17 (Figure 3c). This indicates, that PCNA and
hRad17 do not interact in HU treated cells. Alter-
natively, the interaction might be transient or mediated
by other proteins, e.g. the small hRF-C subunits and
was therefore not detected under our immunoprecipita-
tion conditions.
Figure 1 HRad7 is constitutively nuclear protein during the cell cycle. (a) The subcellular localization of hRad17 in Hela cells
synchronized in the cell cycle phases G0/G1 (left row), S (middle row) or G2/M (right row) was detemined by immunocytochemistry
using antibody sc-5613 recognizing hRad17 and Cy.3 coupled secondary antibody (red fluorescence). Control stainings were per-
formed with DAPI (4,6-diamido-2-phenylindole, blue fluorescence) or antibody PC10 recognizing the nuclear replication prtein
PCNA in combination with DTAF coupled secondary antibody (green fluorescence). The cell cycle distribution of each cell popula-
tion was analysed by propidium iodide staining and FACS scan (upper panels). Bar 32 mm. (b) Immunoblot analysis with Hela total
extracts (t.e.) and Dot blot analysis with purified proteins revealing that sc-5613 specifically recognized hRad17. Aldolase and
GSGEF-2 are controls
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Colocalization of hRad17 with sites of DNA replication in
S phase
Genetic studies in yeast positioned Rad17/Rad24 and
RF-C subunits at the basis of the cell cycle responses
to DNA replication block and DNA damage (Lindsay
et al., 1998; Walworth and Bernards, 1996; de la Torre-
Ruiz et al., 1998; Sugimoto et al., 1996; Shimada et al.,
1999). Genetic and biochemical analyses in yeast also
proved a functional and physical interaction between
Rad17/Rad24 and RF-C subunits (Shimada et al.,
1999; Shimomura et al., 1998; Green et al., 2000; Naiki
et al., 2000). This suggests a sensor or signal
transmitter role for the Rad17/RF-C or Rad24/RF-C
complexes in the DNA replication and/or DNA
damage checkpoint pathways. A sensor of replication
block or DNA damage is expected to accompany the
replisome to survey the smooth progression of DNA
replication and to be recruited to stalled replication
forks or to sites of DNA damage. The distribution of
replication sites shows distinct patterns in different
stages of S phase and can be monitored by
immunocytochemical detection of bromodeoxyuridine
(BrdU) incorporation or of PCNA. In early S phase
replication sites are distributed throughout the nucleus
with the exception of condensed heterochromatin and
nucleoli. Replication sites are very small, discrete and
number several hundred. As cells proceed from early to
mid S phase, nuclei show no unlabelled areas and a
fairly uniform staining of the nucleus. In the late S
phase the perinucleolar region replicates first, often
leading to ring structures. Replication of the bulk of
heterochromatin follows appearing as a pattern of
large discrete foci. At this stage heterochromatin at the
nuclear periphery is also replicated. At the end of S
phase replication is confined to the nuclear periphery
(Bravo and MacDonald-Bravo, 1987; Fox et al., 1991).
We investigated the subnuclear localization of BrdU
incorporation and of hRad17 in S phase Hela cells.
hRad17 and sites of DNA replication colocalized in the
early S phase of the cell cycle and to a low extent in
mid S phase. Only a very petty colocalization was
found in late S phase (Figure 4). Thus, hRad17 might
Figure 2 hRF-C p37 is recruited to DNA upon treatment with
hydroxyurea or 4-nitroquinoline. Replication and checkpoint
Rad proteins were detected by immunoblot analysis using total
extracts from equivalent cell numbers of not synchronized Hela
cells (n.s.), of untreated Hela cells in S phase (un) and of Hela
cells in S phase treated with hydroxyurea (HU) or with 4-nitro-
quinoline (4-NQO). (a) Total extracts were prepared using 140
or 400 mM KCl as indicated, 50 mg/ml ethidiumbromide and
0.1% Triton X-100. Upon treatment with HU or 4-NQO hRad9
is hyperphosphorylated indicating checkpoint activation and
hRF-C p37 is getting more extraction resistant at 140 mM KCl.
(b) Equivalent cell numbers of untreated, HU or 4-NQO treated
Hela cells in S phase were lysed in lysis buffer containing
140 mM KCl, 0.1% Triton X-100 in the absence (7) or presence
(+) of 100 mg S7 nuclease to digest cellular DNA. After treat-
ment with S7 nuclease extraction resistant hRF-C p37 is released.
(c,d) Total extracts for loading controls were produced by boiling
of equivalent cell numbers in 26 SDS–PAGE sample buffer and
analysed by immunoblot analysis using antibodies recognizing b-
actin, hRad17, hRF-C p37 and PCNA
Figure 3 Interactions between hRF-Cp37, PCNA and check-
point Rad proteins. Co-immunoprecipitation experiments with to-
tal extracts of HU treated S phase Hela cells using the following
antibodies for immunoprecipitation (IP): (a) anti hRF-C p37
polyclonal rabbit antiserum control serum from rabbits (control),
(b,c) monoclonal antibody PC10 specific for human PCNA or
monoclonal antibody HA.11. Immunoprecipitated proteins were
detected by immunoblot analysis using anti hRF-C p37 polyclo-
nal rabbit antiserum. Anti hRad17 polyclonal antibody sc-5613,
PC10, or anti hRad9 polyclonal antibody sc-8324 as indicated
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directly monitor the accuracy of DNA replication by
associating with the replication machinery in early S
phase. We could confirm these data by investigating
the subnuclear localization of hRad17 and the
replication protein PCNA (Figure 5a).
Enhanced colocalization of hRad17 with PCNA in late S
phase upon treatment with HU or 4-NQO
Our immunocytochemical studies combined with
epifluorescence microscopy showed, that hRad17
colocalized with PCNA in the early S phase and to a
low extent in the mid S phase of the cell cycle in
untreated Hela cells (Figure 5a) and in cells treated
with HU (Figure 5b) or 4-NQO (Figure 5c). By
immunocytochemistry, epifluorescence and confocal
microscopy we observed enhanced colocalization of
hRad17 with PCNA in the late S phase of the cell cycle
upon replication block or DNA damage. In untreated
cells hRad17 only weakly colocalized with perinucleo-
lar PCNA assemblies characteristic for an early
stadium in late S (Figure 5a,d, upper panel). It only
marginally colocalized with large PCNA speckles
observed in later stages of the late S phase (Figure
5a,d, middle and lower panel). After treatment of Hela
cells with HU hRad17 showed enhanced colocalization
with PCNA arranged around nucleoli (Figure 5b, e,
upper panel), with large PCNA speckles and with
PCNA distributed in small foci throughout the
nucleoplasm (Figure 5b,e, middle and lower panel).
In cells treated with 4-NQO hRad17 colocalized
stronger with perinucleolar PCNA assemblies than in
untreated cells (Figure 5c,f, upper panel). In later
stages of late S we observed only marginal colocaliza-
tion of hRad17 with PCNA (Figure 5c,f middle and
lower panel). In untreated and treated cells in S phase
hRad17 was distributed in foci throughout the
nucleoplasm, which form regions of higher and lower
density and often are arranged in horseshoe-like
assemblies (Figure 5a – f). Upon treatment of Hela
cells with HU or 4-NQO the nucleoplasmic PCNA
immunofluorescence was slightly or strongly enhanced
due to recruitment of PCNA to the chromatin (Sasaki
et al., 1993; Miura, 1999).
Discussion
Recently Chen et al. (2001a) reported the discovery of
alternative hRad17 splicing products encoding different
hRad17 polypeptides. The hRad17 version we investi-
gated in our study corresponds to the usually described
and by far most abundant 670 amino acid version,
which was detected in all cell cycle phases in total
extracts of unirradiated and g-irradiated human
fibroblasts. We could additionally show that in Hela
cells hRad17 is a constitutively nuclear protein during
the cell cycle. Therefore, its function is not regulated by
nuclear import or export. In contrast, hHus1 is
translocated into the nucleus upon DNA damage or
upon replication inhibition (Komatsu et al., 2000). Our
discovery, that endogenous hRad17 and hRF-C p37
interact under conditions of replication block is
consistent with data from studies in fission yeast.
Figure 4 Colocalization of hRad17 with sites of DNA replication. The subnuclear localization of hRad17 was analysed by immu-
nocytochemistry with unsynchronized Hela cells using antibody sc-5613 and Cy.3-coulpled secondary antibody (red fluorescence, left
panels). DNA replication sites were marked by incorporation of the nucleotide analogue bromodeoxyuridine (BrdU) and visualized
by immunocytochemistry using anti BrdU antibody 3D4 and DTAF-coupled secondary antibody (green fluorescence, middle pa-
nels). Pictures were taken using an Olympus BX51 fluorescence microscope connected to a DP50 digital camera system. Panels
on the right show the merged anti hRad17 and anti BrdU immunofluorescences. Cells were attributed to early, mid and late S phase
according to Bravo and McDonald-Bravo (1987) and Fox et al. (1991)
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These show that the hRF-C p37 homologue Rfc2
associates with overexpressed Rad17 in untreated as
well as HU treated yeast (Kai et al., 2001). Like in
fission yeast, hRF-C p140 did not co-immunoprecipi-
tate hRad17 in extracts of HU treated Hela cells (our
unpublished data), indicating that the two proteins
participate in two distinct hRF-C complexes.
Zou et al. (2002) demonstrated that in Hela cells
UV or HU treatment enhances the phosphorylation of
hRad17 on the chromatin. Furthermore, hRad17 or
hHus1 are required to load hRad9 onto the chromatin
upon UV treatment or HU treatment. Phosphoryla-
tion of hRad17 by checkpoint kinases regulates its
interaction with hRad1 (Bao et al., 2001). Our co-
immunoprecipitation experiments revealed an interac-
tion of PCNA with hRad9 and with hRF-Cp37 in HU
treated S phase Hela cells. Previous studies by
Komatsu et al. (2000) reported an association of
hHus1 with PCNA upon treatment of cells with HU
or ionizing radiation. Our immunocytochemichal
studies additionally showed that hRad17 colocalized
with sites of BrdU incorporation or PCNA in the
early S phase and to a low extent in mid S phase,
suggesting that in these stages of S phase hRad17
accompanies the replisome. The hRad17/RF-C
complex could function as a surveyor or sensor
monitoring the accuracy of DNA replication and the
integrity of the DNA. In the late S phase of the cell
cycle the colocalization of hRad17 with PCNA was
enhanced after treatment with HU or 4-NQO. After
HU treatment hRad17 was found to colocalize with
perinucleolar PCNA assemblies, with large PCNA
speckles and with small PCNA foci in the nucleo-
plasm. Bravo (1986) and Bravo and MacDonald-
Bravo (1985) reported, that the staining of PCNA
does not change significantly upon treatment of cells
with HU or aphidicolin at any stage during S phase
and that the staining pattern is maintained as long as
DNA synthesis is inhibited. This suggests, that
hRad17 is recruited to sites of replication block. In
the light of the known data our failure to co-
immunopreciptate PCNA and hRad17 most probably
reflects the indirect nature of this interaction. hRF-
Cp37 could serve as the connecting link between
hRad17 and PCNA, because it interacted in HU
treated cells with both proteins. Since it has been
shown that hRad17 interacts with the small hRF-C
subunits (Lindsey-Boltz et al., 2001) and that small
hRF-C subunits interact with PCNA, an interaction of
hRad17 with PCNA could also be mediated by one of
the other small RF-C subunits, e.g. hRF-C p36
(Mossi et al., 1997). In the presence of UV like
damage hRad17 showed enhanced colocalization with
perinucleolar foci in late S phase, but not in later
stages of late S. This suggests a recruitment of
hRad17 to sites of DNA damage in an early stadium
of late S.
We propose the following model for the role of
hRad17 in the DNA replication checkpoint pathway
(Figure 6): hRad17 is recruited to sites of replication
block in late S phase and functions as a sensor or as a
signal transducer. hRad17 loads the hRad9/hHus1/
hRad1 complex onto the chromatin and enables it to
interact with PCNA arrested at sites of replication
block. hHus1 mediates the phosphorylation of hRad17
by the checkpoint kinase ATR, which could represent
an additional sensor for replication block (Zou et al.,
2002). Phosphorylation of hRad17 regulates its inter-
action with hRad1. PCNA then might serve as a
coordinating platform for DNA replication checkpoint
activation, DNA repair and the resumption of DNA
replication. The role of the hRad9/hHus1/hRad1
complex in the recovery process from replication block
is currently a subject of intensive studies.
Materials and methods
Synchronization of Hela cells
Synchronization of Hela cells in G1 was achieved by serum
starvation for 48 h with DMEM/0.5% (v/v) FCS and
treatment with aphidicolin (3 mg/ml medium) for 26 h. Hela
cells were synchronized in S phase by serum starvation with
DMEM/0.5% (v/v) FCS for 48 h, treatment with 3 mg/ml
medium aphidicolin for 24 h and subsequent growth in
DMEM/10% (v/v) FCS for 5 h 30 min. Synchronization in
G2/M was achieved by addition of 150 ng/ml nocodazole to
the medium for 15 h and 1 h release from cell cycle arrest at
G2/M. The cell cycle status of synchronized cells was
analysed by propidium iodide staining of the DNA and
FACS scan analysis.
Treatment of cells to cause replication block or DNA damage
Hela cells synchronised in S phase were incubated for 1 h
with medium containing 10 mM HU or 2 mg/ml 4-NQO.
Dot blot analysis
500 ng of GSThRad17 (103 kD), aldolase (40 kD) or GST-
GEF2 (43 kD) were spotted onto a nitrocellulose membrane
and subjected to immunoblot analysis using anti hRad17
antibody sc-5613.
Extraction test
Hela cells were synchronized in S phase, left untreated or
treated with HU or 4-NQO as described above. Cells were
harvested by trypsinization. Total extracts were prepared by
adding 170 ml HEPES/Triton lysis buffer per 1.56 106 cells
and incubation for 22 min on ice. Lysis buffer contained 140
or 400 mM KCl in 40 mM HEPES pH 7.4, 10 mM MgCl2,
1 mM EDTA, 2 mg/ml leupeptin, 1 mg/ml pepstatin, 1 mg/ml
bestatin, 1 mM PMSF, 50 mM NaF, 1 mM Na3VO4, 20 ng/ml
microcystin LR, 10 mM glycerophosphate, 50 mg/ml ethi-
diumbromide, 1 mM DTT, 0.1% (v/v) Triton X-100. S7
nuclease digestion of cellular DNA was performed by lysing
Hela cells in the same way as described above in HEPES/
Triton lysis buffer containing 140 mM KCl without EDTA
and ethidiumbromide, but supplemented with 2 mM CaCl2
and 100 mg S7 nuclease/170 ml lysis buffer. After lysis extracts
were centrifuged 5 min at 20 800 g at 48C. To the super-
natants 20 ml 106 SDS–PAGE sample buffer were added,
samples were boiled for 5 min at 1008C and subjected to
immunoblot analysis.
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Immunoprecipitations
Hela cells were synchronized in S phase, treated with HU and
harvested by trypsinization. For immunoprecipitation of
hRF-C p37 total extracts were prepared by incubating cells
22 min on ice in 170 ml Tris/NP40 lysis buffer (50 mM Tris
pH 7.5, 140 mM KCl, 10 mM MgCl2, 1 mM EDTA, 2 mg/ml
leupeptin, 1 mg/ml pepstatin, 1 mg/ml bestatin, 1 mM PMSF,
50 mM NaF, 1 mM Na3VO4, 20 ng/ml microcystin LR,
10 mM glycerophosphate, 50 mg/ml ethidiumbromide, 1 mM
DTT, 0.1% (v/v) NP40) per 1.56106 cells. Extracts were
centrifuged 5 min at 20.800 g at 48C. Extracts were diluted
1 : 1 to adjust the KCl concentration to 100 mM and the
NP40 concentration to 0.5% (v/v). To 240 ml diluted extract
5 ml anti hRF-C p37 antiserum or control serum from
unimmunized rabbits were added and incubated for 2 h
30 min on a rocking platform at 48C. 20 ml equilibrated
protein A sepharose were added to each sample and the
samples were incubated on a rocking platform for further
60 min at 48C. After washing four times with Tris/NP40
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wash buffer (50 mM Tris pH 7.5, 100 mM KCl, 10 mM
MgCl2, 1 mM EDTA, 2 mg/ml leupeptin, 1 mg/ml pepstatin,
1 mg/ml bestatin, 1 mM PMSF, 50 mM NaF, 1 mM Na3VO4,
20 ng/ml microcystin LR, 10 mM glycerophosphate, 50 mg/ml
ethidiumbromide, 1 mM DTT, 0.5% (v/v) NP-40) bound
proteins were eluted from protein A sepharose by addition of
70 ml 26 SDS–PAGE sample buffer. For immunoprecipita-
tion of PCNA total extracts were prepared by lysing Hela
cells in HEPES/Triton lysis buffer containing 140 mM KCl as
described in the paragraph ‘Extraction test’. To 120 ml total
extract 1 mg PC10 or control antibody HA.11 were added
and incubated for 2 h 30 min on a rocking platform at 48C.
After addition of 20 ml equilibrated protein G sepharose the
samples were incubated for further 90 min on a rocking
platform at 48C. After washing four times with HEPES/
Triton lysis buffer without ethidiumbromide containing
200 mM KCl bound proteins were eluted from protein G
sepharose by addition of 70 ml 26 SDS –PAGE sample
buffer. Samples were subjected to immunoblot analysis.
Immunocytochemistry
Hela cells were seeded on Lab-Tek chamber slides (Nalge
Nunc International), synchronized in G0/G1, in S phase or in
the G2/M phase of the cell cycle. For subcellular localization
of hRad17 and simultaneous DAPI (4,6-diamido-2-phenylin-
dole) staining cells were fixed 20 min at room temperature
with 4% (w/v) PFA/PBS, then washed three times with PBS
at room temperature and incubated for 5 min with PBS/0.2%
(v/v) Triton X-100. Unspecific antibody binding sites were
blocked by incubation with blocking solution (PBS/1% (w/v)
BSA/0.03% (v/v) Tween-20) for 20 min. Cells were incubated
for 1 – 2 h with anti hRad17 antibody sc-5613 (1 : 300 in
blocking solution), then washed twice 5 min with PBS and
once with blocking solution at room temperature. Cells were
incubated for 45 min at room temperature with Cy.3
conjugated goat anti rabbit antibody (1 : 300 in blocking
solution), washed three times 5 min with PBS at room
temperature, incubated 5 min at room temperature with
Figure 5 Enhanced colocalization of hRad 17 with PCNA in late S phase after HU or 4-NQO treatment. Hela cells synchronized
in S phase were left untreated or treated with HU or 4-NQO. (a – f) The subnuclear localizations of hRad17 (red fluorescence, left
panels) and PCNA (green fluorescence, middle panels) were investigated by immunocytochemistry using antibody sc-5613 in com-
bination with Cy.3 coupled secondary antibody and antibody PC10 in combination with DTAF coupled secondary antibody. Panels
on the right show the merged hRad17 and PCNA immunofluorescences. (a-c) Representative cells in early, mid and late S phase
without treatment (a), after HU treatment (b) and after 4-NQO treatment (c) are shown. Captures were made using an Olympus
BX51 fluorescence microscope coupled to at DP50 digital camera system. Panels (d – f) show pictures of representative cells in
the late S phase taken using a Leica TCS SP2 confocal laser scanning microscope: (d) without treatment, (e) after HU treatment
and (f) after 4-HQO treatment. (g) FACS scan analysis of the cell cycle distribution at the timepoint of treatment (S phase control
1), of untreated cells (S phase control 2), of HU or of 4-NQO treatment cells (S phase +HU, S phase +4-NQO). The top panel
shows the cell cycle distribution of unsynchronized cells (unsynch.)
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50 ng/ml DAPI/PBS for DNA staining and washed twice
5 min with PBS at room temperature. Finally, cells were
covered with vectashield mounting medium (Vector Labora-
tories), and coverslips were fixed with nail polish.
For colocalization of hRad17 with sites of BrdU
incorporation unsynchronized Hela cells were incubated
30 min with medium containing 10 mM BrdU. Cells were
washed with PBS and fixed for 2 min with 3% (w/v)
paraformaldehyde/PBS at room temperature, washed with
PBS, then fixed with 708C cold 30% (v/v) MetOH/PBS, 60%
(v/v) MetOH/PBS, 100% MetOH, 60% (v/v) MetOH/PBS,
30% (v/v) MetOH/PBS for 2 min each. Cells were washed
twice with PBS at room temperature and incubated for 5 min
with PBS/0.2% (v/v) Triton X-100. Unspecific antibody
binding sites were blocked by incubation with blocking
solution (PBS/1% (w/v) BSA/0.03% (v/v) Tween-20) for
20 min. Cells were incubated with sc-5613 (1 : 300 in blocking
solution) for 1 – 2 h at room temperature, then washed twice
5 min with PBS and once with blocking solution at room
temperature. Cells were then incubated for 45 min at room
temperature with Cy.3 conjugated goat anti rabbit antibody
(1 : 300 in blocking solution), washed three times with PBS,
refixed for 5 – 10 min with 3% (w/v) PFA/PBS at room
temperature, washed three times with PBS and incubated
10 – 15 min with blocking solution. DNA was denatured by
10 min incubation with 2 N HCl/0.5% (v/v) Triton X-100 at
room temperature. Cells were then washed once with 0.1 M
Na2B4O7 pH 8.5 for 5 min and twice with PBS for 5 min and
then incubated with anti BrdU antibody 3D4 (1 : 100 in
blocking solution) for 1 h 30 min. After washing twice with
PBS for 5 min and once with blocking solution for 5 min
cells were incubated 45 min with DTAF conjugated goat anti
mouse antibody (1 : 500 in blocking solution). After washing
the cells three times 5 min with PBS at room temperature,
cells were covered with mounting medium and coverslips
were fixed with nail polish.
For colocalization of hRad17 and PCNA Hela cells
synchronized in S phase were fixed for 2 min with 4% (w/v)
paraformaldehyde/PBS at room temperature, washed with
PBS, then fixed with 7208C cold 30% (v/v) MetOH/PBS,
60% (v/v) MetOH/PBS, 100% MetOH, 60% (v/v) MetOH/
PBS, 30% (v/v) MetOH/PBS for 2 min each. Cells were
washed twice with PBS at room temperature and incubated
for 5 min with PBS/0.2% (v/v) Triton X-100. Unspecific
antibody binding sites were blocked by incubation with
blocking solution (PBS/1% (w/v) BSA/0.03% (v/v) Tween-
20) for 20 min. Cells were incubated with anti sc-5613
(1 : 300 in blocking solution) and mouse monoclonal anti
PCNA antibody PC10 (1 : 500 in blocking solution) for 1 –
2 h at room temperature. Cells were then washed twice for
5 min with PBS and once with blocking solution at room
temperature. Cells were incubated for 45 min at room
temperature with Cy.3 conjugated goat anti rabbit antibody
(1 : 300 in blocking solution) and DTAF conjugated goat
anti mouse antibody (1 : 500 in blocking solution). After
washing the cells three times 5 min with PBS at room
temperature, cells were covered with vectashield mounting
medium (Vector Laboratories), and coverslips were fixed
with nail polish.
Antibodies
Anti PCNA: PC10 (sc-56, Santa Cruz Biotechnology), anti
Rad17: sc-5613 (Santa Cruz Biotechnology), anti hRF-C
p140: monoclonal antibody no. 11 (gift of Bruce Stillman),
anti hRF-C p37: rabbit polyclonal serum (gift of Jerard
Hurwitz), anti hRad9: sc-8324 (Santa Cruz Biotechnology),
anti b-actin (AC-15, Sigma, gift of Stefan Keller), antiBrdU
(3D4, BD PharMingen), Cy.3 goat anti rabbit polyclonal
(Jackson ImmunoResearch Laboratories), DTAF goat anti
mouse polyclonal (Anawa Trading SA).
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